Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

Similar articles for PubMed (Select 21908416)

1.

Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease.

Lian M, Hewitson TD, Wigg B, Samuel CS, Chow F, Becker GJ.

Nephrol Dial Transplant. 2012 Mar;27(3):906-12. doi: 10.1093/ndt/gfr495. Epub 2011 Sep 8.

2.

Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.

Taira M, Toba H, Murakami M, Iga I, Serizawa R, Murata S, Kobara M, Nakata T.

Eur J Pharmacol. 2008 Jul 28;589(1-3):264-71. doi: 10.1016/j.ejphar.2008.06.019. Epub 2008 Jun 10.

PMID:
18582458
3.

Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.

Kang MJ, Ingram A, Ly H, Thai K, Scholey JW.

Kidney Int. 2000 Oct;58(4):1677-85.

4.

Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats.

Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibashi S.

Kidney Int. 2004 Oct;66(4):1493-502.

PMID:
15458443
5.

Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats.

Han KH, Kang YS, Han SY, Jee YH, Lee MH, Han JY, Kim HK, Kim YS, Cha DR.

Kidney Int. 2006 Jul;70(1):111-20. Epub 2006 May 24.

PMID:
16723984
6.

Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.

Kang YS, Ko GJ, Lee MH, Song HK, Han SY, Han KH, Kim HK, Han JY, Cha DR.

Nephrol Dial Transplant. 2009 Jan;24(1):73-84. doi: 10.1093/ndt/gfn448. Epub 2008 Aug 5.

7.

Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model.

Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y, Hirokoshi K, Sugiyama H, Yamasaki Y, Eguchi K, Makino H.

Diabetes. 2005 Oct;54(10):2891-903. Erratum in: Diabetes. 2006 Sep;55(9):2665.

8.

The protective effect of Salvia miltiorrhiza in an animal model of early experimentally induced diabetic nephropathy.

Lee SH, Kim YS, Lee SJ, Lee BC.

J Ethnopharmacol. 2011 Oct 11;137(3):1409-14. doi: 10.1016/j.jep.2011.08.007. Epub 2011 Aug 11.

PMID:
21856399
9.

Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats.

Tone A, Shikata K, Sasaki M, Ohga S, Yozai K, Nishishita S, Usui H, Nagase R, Ogawa D, Okada S, Shikata Y, Wada J, Makino H.

Diabetologia. 2005 Nov;48(11):2402-11. Epub 2005 Oct 18.

PMID:
16231067
10.

Protective effect of Icariin on the early stage of experimental diabetic nephropathy induced by streptozotocin via modulating transforming growth factor β1 and type IV collagen expression in rats.

Qi MY, Kai-Chen, Liu HR, Su YH, Yu SQ.

J Ethnopharmacol. 2011 Dec 8;138(3):731-6. doi: 10.1016/j.jep.2011.10.015. Epub 2011 Oct 19.

PMID:
22027446
11.

FK506 ameliorates renal injury in early experimental diabetic rats induced by streptozotocin.

Qi XM, Wu YG, Liang C, Zhang P, Dong J, Ren KJ, Zhang W, Fang F, Shen JJ.

Int Immunopharmacol. 2011 Oct;11(10):1613-9. doi: 10.1016/j.intimp.2011.05.023. Epub 2011 Jun 1.

PMID:
21640200
12.

Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade.

Bonnet F, Candido R, Carey RM, Casley D, Russo LM, Osicka TM, Cooper ME, Cao Z.

J Hypertens. 2002 Aug;20(8):1615-24.

PMID:
12172324
13.

Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats.

Yuan J, Jia R, Bao Y.

J Renin Angiotensin Aldosterone Syst. 2007 Sep;8(3):118-26.

PMID:
17907099
14.

The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes.

Wong SE, Samuel CS, Kelly DJ, Zhang Y, Becker GJ, Hewitson TD.

Protein Pept Lett. 2013 Sep;20(9):1029-38.

PMID:
23343143
15.

Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.

Yamashita H, Nagai Y, Takamura T, Nohara E, Kobayashi K.

Metabolism. 2002 Apr;51(4):403-8.

PMID:
11912544
16.

Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat.

Pessôa BS, Peixoto EB, Papadimitriou A, Lopes de Faria JM, Lopes de Faria JB.

J Renin Angiotensin Aldosterone Syst. 2012 Mar;13(1):56-66. doi: 10.1177/1470320311422581. Epub 2011 Oct 10.

PMID:
21987533
17.

Role of aldosterone in diabetic nephropathy.

Cha DR, Kang YS, Han SY, Jee YH, Han KH, Kim HK, Han JY, Kim YS.

Nephrology (Carlton). 2005 Oct;10 Suppl:S37-9.

PMID:
16174286
18.

Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production.

Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, Hirakawa M, Taniguchi M, Masutani K, Iida M.

Nephrol Dial Transplant. 2011 Aug;26(8):2475-84. doi: 10.1093/ndt/gfq750. Epub 2011 Jan 10.

19.

Spontaneous remission of diabetes arrests progression of nephropathy in streptozotocin-treated spontaneously hypertensive rats.

Iwase M, Wakisaka M, Sato Y, Yoshinari M, Nunoi K, Ochi N, Fujishima M.

Diabetes Res Clin Pract. 1994 Jan;22(2-3):129-37.

PMID:
8200294
20.

Early, but not advanced, glomerulopathy is reversed by pancreatic islet transplants in experimental diabetic rats: correlation with glomerular extracellular matrix mRNA levels.

Pugliese G, Pricci F, Pesce C, Romeo G, Lenti E, Caltabiano V, Vetri M, Purrello F, Di Mario U.

Diabetes. 1997 Jul;46(7):1198-206.

PMID:
9200656
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk